Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy

被引:3
作者
Neutel, Joel [1 ]
Shojaee, Ali [2 ]
Maa, Jen-Fue [2 ]
机构
[1] Orange Cty Res Ctr, Dept Clin Pharmacol, Tustin, CA 92780 USA
[2] Daiichi Sankyo Inc, Parsippany, NJ USA
关键词
Amlodipine; Angiotensin II receptor blocker; Blood pressure; Calcium channel blocker; Combination therapy; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; OLMESARTAN MEDOXOMIL; BLOOD-PRESSURE; COMBINATION; AMLODIPINE; TRIAL;
D O I
10.1007/s12325-012-0030-z
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
While monotherapy is often recommended as initial treatment, most patients require dose escalation and add-on agents to achieve their blood pressure (BP) goal. This secondary analysis evaluated the efficacy and safety of initiating patients on a regimen of fixed-dose amlodipine (AML)/olmesartan medoxomil (OM) +/- hydrochlorothiazide (HCTZ) who were uncontrolled on prior monotherapy with a calcium channel blocker (CCB) or angiotensin II receptor blocker (ARB). Patients uncontrolled on prior monotherapy with CCB or ARB therapy were initiated on AML/OM 5/20 mg and up-titrated every 4 weeks to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 + HCTZ 12.5 mg, and AML/OM 10/40 + HCTZ 25 mg. Patients were up-titrated to a higher AML/OM dose if mean seated cuff BP (SeBP) was a parts per thousand yen120/70 mmHg, and up-titrated to any HCTZ dose if mean SeBP was a parts per thousand yen125/75 mmHg. The primary efficacy endpoint was the cumulative proportion of patients achieving a seated cuff systolic BP (SeSBP) goal of < 140 mmHg (< 130 mmHg for patients with diabetes) after 12 weeks. Secondary endpoints included mean change from baseline in SeBP and ambulatory BP, ambulatory BP target achievement, and safety. For the prior CCB (n = 118; baseline SeBP: 153.4/91.5 mmHg) and ARB (n = 237; 154.6/92.6 mmHg) groups, SeSBP goal achievement after 12 weeks was 72.7% and 76.9%, respectively. Mean changes (+/- SE) from baseline in SeBP were dose proportional for prior CCB and ARB patients, ranging from -9.9 (+/- 1.25)/-5.8 (+/- 0.83) mmHg and -13.9 (+/- 0.79)/-7.6 (+/- 0.47) mmHg at the AML/OM 5/20 mg dose, respectively, to -21.8 (+/- 1.68)/-11.6 (+/-.12) mmHg and -26.2 (+/- 1.31)/-15.0 (+/- 0.86) mmHg at the AML/OM 10/40 mg + HCTZ 25 mg dose (P < 0.0001 for all). An AML/OM-based titration regimen was efficacious in achieving BP goal in patients uncontrolled on prior monotherapy with a CCB or ARB.
引用
收藏
页码:508 / 523
页数:16
相关论文
共 50 条
[21]   Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan [J].
Ono, Minamo ;
Fukuda, Michio ;
Miura, Toshiyuki ;
Mizuno, Masashi ;
Kato, Yoko ;
Sato, Ryo ;
Naito, Takehiro ;
Togawa, Hiroyuki ;
Sasakawa, Yuji ;
Tomonari, Tatsuya ;
Ichikawa, Tadashi ;
Shirasawa, Yuichi ;
Ito, Akinori ;
Yoshida, Atsuhiro ;
Kimura, Genjiro .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2012, 13 (02) :239-243
[22]   Angiotensin II Receptor Blocker-based Therapy in Japanese Elderly, High-risk, Hypertensive Patients [J].
Ogawa, Hisao ;
Kim-Mitsuyama, Shokei ;
Matsui, Kunihiko ;
Jinnouchi, Tomio ;
Jinnouchi, Hideaki ;
Arakawa, Kikuo .
AMERICAN JOURNAL OF MEDICINE, 2012, 125 (10) :981-990
[23]   The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: The OLCA study [J].
Daikuhara, Hiroyuki ;
Kikuchi, Fumi ;
Ishida, Toshihiko .
DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (04) :280-286
[24]   The Efficacy and Safety of Triple vs Dual Combination of Angiotensin II Receptor Blocker and Calcium Channel Blocker and Diuretic: A Systematic Review and Meta-Analysis [J].
Kizilirmak, Pinar ;
Berktas, Mehmet ;
Uresin, Yagiz ;
Yildiz, Okan Bulent .
JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (03) :193-200
[25]   Age- and Sex-Related Differences in Efficacy With an Angiotensin II Receptor Blocker and a Calcium Channel Blocker in Asian Hypertensive Patients [J].
Kario, Kazuomi ;
Hoshide, Satoshi .
JOURNAL OF CLINICAL HYPERTENSION, 2016, 18 (07) :672-678
[26]   Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy [J].
Jun-Ren Zhu ;
Shu-Yang Zhang ;
Ping-Jin Gao .
Archives of Pharmacal Research, 2014, 37 :1588-1598
[27]   Beneficial Effect of Combination Therapy Comprising Angiotensin II Receptor Blocker Plus Calcium Channel Blocker on Plasma Adiponectin Levels [J].
Inoue, Yukiko ;
Kakuma, Tatsuyuki ;
Nonaka, Yoshisuke ;
Sumi, Shunichiro ;
Okamura, Keisuke ;
Kodama, Sunao ;
Ando, Chie ;
Niimura, Hideya ;
Miyoshi, Kei ;
Tsuchiya, Yoshihiro ;
Yamanouchi, Yoshio ;
Urata, Hidenori .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2010, 32 (01) :21-28
[28]   ANGIOTENSIN II RECEPTOR BLOCKER IS PREFERABLE TO CALCIUM CHANNEL BLOCKER TO IMPROVE NOCTURNAL DIPPING PATTERN IN UNTREATED HYPERTENSIVES [J].
Cho, Jin-Man ;
Hwang, Hui-Jeong ;
Jin, Eun-Sun ;
Park, Chang-Bum ;
Sohn, Il-Suk ;
Kim, Chong-Jin .
JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (07) :519-519
[29]   The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy [J].
Giles, Thomas D. ;
Oparil, Suzanne ;
Ofili, Elizabeth O. ;
Pitt, Bertram ;
Purkayastha, Das ;
Hilkert, Robert ;
Samuel, Rita ;
Sowers, James R. .
BLOOD PRESSURE MONITORING, 2011, 16 (02) :87-95
[30]   Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker [J].
Furuhashi, Masato ;
Moniwa, Norihito ;
Mita, Tomohiro ;
Fuseya, Takahiro ;
Ishimura, Shutaro ;
Ohno, Kohei ;
Shibata, Satoru ;
Tanaka, Marenao ;
Watanabe, Yuki ;
Akasaka, Hiroshi ;
Ohnishi, Hirofumi ;
Yoshida, Hideaki ;
Takizawa, Hideki ;
Saitoh, Shigeyuki ;
Ura, Nobuyuki ;
Shimamoto, Kazuaki ;
Miura, Tetsuji .
AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (01) :15-21